High-throughput flow cytometry to detect selective inhibitors of ABCB1, ABCC1, and ABCG2 transporters.
暂无分享,去创建一个
Tudor I. Oprea | Irena Ivnitski-Steele | Bruce S Edwards | Tudor I Oprea | Larry A Sklar | Richard S Larson | T. Oprea | S. Winter | B. Edwards | L. Sklar | R. Larson | Debbie Lovato | I. Ivnitski-Steele | Hadya M. Khawaja | Stuart S Winter | Debbie M Lovato | Hadya M Khawaja
[1] R. Layfield,et al. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. , 2007, International journal of oncology.
[2] I. Pastan,et al. Fluorescent cellular indicators are extruded by the multidrug resistance protein. , 1993, The Journal of biological chemistry.
[3] E. Wang,et al. Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. , 2001, Biochemical and biophysical research communications.
[4] Tudor I. Oprea,et al. High-throughput flow cytometry for drug discovery , 2007, Expert opinion on drug discovery.
[5] G. N. Sastry,et al. Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. , 2006, Current drug metabolism.
[6] Lawrence X. Yu,et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. , 2006, Molecular pharmaceutics.
[7] M. Poupon,et al. Response of a multidrug-resistant human small-cell lung cancer xenograft to chemotherapy , 2005, Journal of Cancer Research and Clinical Oncology.
[8] G. Peters,et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. , 2005, Cancer research.
[9] Wolfgang Löscher,et al. Drug resistance in brain diseases and the role of drug efflux transporters , 2005, Nature Reviews Neuroscience.
[10] S. Chong,et al. P-glycoprotein plays a role in the oral absorption of BMS-387032, a potent cyclin-dependent kinase 2 inhibitor, in rats , 2005, Cancer Chemotherapy and Pharmacology.
[11] R. O'connor,et al. The pharmacology of cancer resistance. , 2007, Anticancer research.
[12] G. M. Wilson,et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.
[13] W. Greco,et al. Breast cancer resistance protein (BCRP/MXR/ABCG2) in adult acute lymphoblastic leukaemia: frequent expression and possible correlation with shorter disease‐free survival , 2004, British journal of haematology.
[14] J. Foekens,et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. , 1997, British Journal of Cancer.
[15] P. Houghton,et al. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. , 1989, Biochemical pharmacology.
[16] L A Sklar,et al. High throughput flow cytometry. , 2001, Cytometry.
[17] A. W. Boersma,et al. Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] Thomas D. Y. Chung,et al. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.
[19] Tudor I. Oprea,et al. High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent , 2008, Journal of biomolecular screening.
[20] S. Akiba,et al. Prognostic significance of multidrug resistance protein in adult T-cell leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] S. Kohno,et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. , 2005, Lung cancer.
[22] Katrin Hoffmann,et al. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR – how well do they correlate? , 2005, BMC Genomics.
[23] Mariël Brok,et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. , 2004, Blood.
[24] D. Clarke,et al. Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux , 2005, The Journal of Membrane Biology.
[25] R. Pérez-Tomás,et al. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. , 2006, Current medicinal chemistry.
[26] J. Kühnel,et al. Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe , 1997, Leukemia.
[27] Y. Iwamoto,et al. Involvement of P‐glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug‐resistant osteosarcoma and Ewing's sarcoma cells , 2006, International journal of cancer.
[28] M. Gottesman,et al. Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.
[29] D. Hipfner,et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. , 1994, Cancer research.
[30] L. O’Driscoll,et al. Investigation of MRP‐1 protein and MDR‐1 P‐glycoprotein expression in invasive breast cancer: A prognostic study , 2004, International journal of cancer.
[31] T. Kubota,et al. Resistant mechanisms of anthracyclines — pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues , 2001, Breast cancer.
[32] P. Korošec,et al. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. , 2006, Lung cancer.
[33] T. Efferth,et al. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. , 2007, Biochimica et biophysica acta.
[34] Richard S Larson,et al. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2007, Blood.
[35] Richard S Larson,et al. Genetic alterations determine chemotherapy resistance in childhood T‐ALL: modelling in stage‐specific cell lines and correlation with diagnostic patient samples , 2007, British journal of haematology.
[36] B. Sarkadi,et al. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. , 1994, Biochimica et biophysica acta.
[37] D. Steinbach,et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia , 2002, Leukemia.
[38] Bruce S Edwards,et al. High‐throughput flow cytometry: Validation in microvolume bioassays , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[39] M. Hennessy,et al. A primer on the mechanics of P-glycoprotein the multidrug transporter. , 2007, Pharmacological research.
[40] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[41] A. Knapton,et al. Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. , 2000, The Journal of pharmacology and experimental therapeutics.
[42] R. Larsson,et al. Microfluorometric evaluation of calcein acetoxymethyl ester as a probe for P-glycoprotein-mediated resistance: effects of cyclosporin A and its nonimmunosuppressive analogue SDZ PSC 833. , 1994, Experimental cell research.
[43] B. Uggla,et al. BCRP mRNA expression v. clinical outcome in 40 adult AML patients. , 2005, Leukemia research.
[44] O. Legrand,et al. Breast Cancer Resistance Protein and P-Glycoprotein in 149 Adult Acute Myeloid Leukemias , 2004, Clinical Cancer Research.
[45] Y. Sugimoto,et al. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure–activity relationship , 2007, Cancer Chemotherapy and Pharmacology.